How To Optimize A Clinical Scale Manufacturing Process For Commercial Production

Ensuring a Seamless Technology Transfer and Commercial Production Readiness for R-Pharm’s olokizumab in Europe

In this case study, you will discover more about how the R-Pharm Group collaborates with MilliporeSigma’s BioReliance® End-to-End Solutions to manufacture olokizumab for commercial production.

The clinical scale process was transferred to MilliporeSigma’s Biodevelopment Center in Martillac, France for process scaling, fitting and method validation. The initial phase of the project was focused on optimizing upstream and downstream processes to create a state-of-the art end-to-end workflow for GMP production using single-use technologies. The new process reduced manufacturing time by approximately 40 percent compared to the original approach.